Clinical Trials Browser

Phase 2 × Recruiting × INDUSTRY × Clear all

NCT04634552 2026-06-05

MonumenTAL-1

Phase 2 Recruiting

510 enrolled 1 FDA

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

NCT05498428 2026-06-05

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05503797 2026-06-05

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Phase 2 Recruiting

Glioma

NCT05748171 2026-06-05

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05963074 2026-06-05

TAILOR

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06095505 2026-06-05

ALISCA-Lung1

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06500884 2026-06-05

Talisman

Phase 2 Recruiting

Multiple Myeloma

NCT06568939 2026-06-05

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-06-05

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667908 2026-06-05

CONVERGE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07007559 2026-06-05

ASPEN-09-03

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT07149857 2026-06-05

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT07225621 2026-06-05

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

Phase 2 Recruiting

Glioblastoma

NCT07266441 2026-06-05

TRIlogy-3

Phase 2 Recruiting

Multiple Myeloma

NCT07326566 2026-06-05

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Phase 2 Recruiting

Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma

NCT07353957 2026-06-05

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms

NCT07359820 2026-06-05

ReFocus202

Phase 2 Recruiting

Other solid neoplasm

FGFR2 Gene Fusion/Rearrangement

NCT07475806 2026-06-05

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Phase 2 Recruiting

Muscle-invasive Bladder Cancer

NCT06140524 2026-06-04

LINKER-MGUS1

Phase 2 Recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT06463665 2026-06-04

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06760819 2026-06-04

panSOHO

Phase 2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07059845 2026-06-04

FLORENZA

Phase 2 Recruiting

Ovarian Neoplasms

NCT07169851 2026-06-04

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Phase 2 Recruiting

Nausea, Neoplasms, Vomiting, Drug-Related Side Effects and Adverse Reactions

NCT07269782 2026-06-04

A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07287150 2026-06-04

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT07476287 2026-06-04

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT04567420 2026-06-03

DARE

Phase 2 Recruiting

Breast Neoplasms

NCT06745583 2026-06-03

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Phase 2 Recruiting

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT07002034 2026-06-03

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Phase 2 Recruiting

Adjustment Disorders, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Depression, Multiple Sclerosis, Neoplasms, Idiopathic Pulmonary Fibrosis

NCT07284420 2026-06-03

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Phase 2 Recruiting

Myasthenia Gravis

NCT07483554 2026-06-03

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

Phase 2 Recruiting

Gastrointestinal

CLDN18.2 Positive

NCT07623616 2026-06-03

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05283720 2026-06-02

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05952024 2026-06-02

ACRUE

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06228053 2026-06-02

SYNERGY-201

Phase 2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06369831 2026-06-02

HERMIA

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06500273 2026-06-02

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06539182 2026-06-02

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06730347 2026-06-02

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Phase 2 Recruiting

Endometrial Neoplasms

NCT06820463 2026-06-02

AndroMETa-CRC

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase 2 Recruiting

Metastatic Hormone-sensitive Prostate Cancer

NCT07023289 2026-06-02

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Phase 2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT07024784 2026-06-02

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT07227311 2026-06-02

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Recruiting

Multiple Myeloma

NCT07227350 2026-06-02

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Phase 2 Recruiting

Carcinoma, Basal Cell

NCT07288177 2026-06-02

RAINFOL-05

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07539311 2026-06-02

RAINFOL-09

Phase 2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms

NCT06096779 2026-06-01

Kirros

Phase 2 Recruiting

Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT06474806 2026-06-01

uTRACE-101

Phase 2 Recruiting

Prostatic Neoplasms